John Mohr

2.1k total citations
49 papers, 1.5k citations indexed

About

John Mohr is a scholar working on Epidemiology, Infectious Diseases and Pharmacology. According to data from OpenAlex, John Mohr has authored 49 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Epidemiology, 20 papers in Infectious Diseases and 15 papers in Pharmacology. Recurrent topics in John Mohr's work include Antimicrobial Resistance in Staphylococcus (14 papers), Antibiotics Pharmacokinetics and Efficacy (13 papers) and Antibiotic Resistance in Bacteria (10 papers). John Mohr is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (14 papers), Antibiotics Pharmacokinetics and Efficacy (13 papers) and Antibiotic Resistance in Bacteria (10 papers). John Mohr collaborates with scholars based in United States, Australia and France. John Mohr's co-authors include Barbara E. Murray, Audrey Wanger, Luis Ostrosky‐Zeichner, Katie J. Suda, Helen W. Boucher, John Rex, Grace M. Thorne, Judith N. Steenbergen, Thomas P. Lodise and José E. Rodríguez and has published in prestigious journals such as Clinical Infectious Diseases, Journal of Clinical Microbiology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

John Mohr

47 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Mohr United States 21 721 472 378 369 287 49 1.5k
Katie E. Barber United States 21 827 1.1× 471 1.0× 405 1.1× 421 1.1× 371 1.3× 89 1.5k
Brian J. Werth United States 25 815 1.1× 320 0.7× 318 0.8× 488 1.3× 278 1.0× 49 1.4k
H. David Friedland United States 19 958 1.3× 529 1.1× 594 1.6× 440 1.2× 345 1.2× 39 1.5k
Jon Bruss United States 22 918 1.3× 431 0.9× 434 1.1× 471 1.3× 248 0.9× 33 1.9k
Christopher W. Crank United States 19 842 1.2× 462 1.0× 195 0.5× 481 1.3× 190 0.7× 25 1.4k
Chris M. Pillar United States 23 623 0.9× 287 0.6× 484 1.3× 291 0.8× 573 2.0× 45 1.4k
Pamela Moise United States 19 1.2k 1.7× 522 1.1× 440 1.2× 749 2.0× 221 0.8× 38 1.6k
Deborah C. Draghi United States 22 783 1.1× 513 1.1× 447 1.2× 546 1.5× 742 2.6× 33 1.9k
Sorana Segal‐Maurer United States 22 707 1.0× 593 1.3× 254 0.7× 176 0.5× 466 1.6× 63 1.6k
James C. Hurley Australia 23 549 0.8× 737 1.6× 221 0.6× 369 1.0× 211 0.7× 107 2.3k

Countries citing papers authored by John Mohr

Since Specialization
Citations

This map shows the geographic impact of John Mohr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Mohr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Mohr more than expected).

Fields of papers citing papers by John Mohr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Mohr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Mohr. The network helps show where John Mohr may publish in the future.

Co-authorship network of co-authors of John Mohr

This figure shows the co-authorship network connecting the top 25 collaborators of John Mohr. A scholar is included among the top collaborators of John Mohr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Mohr. John Mohr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Andre, Anthony D., et al.. (2024). Human Factors Validation of a Wearable, On-Body Infusor for Subcutaneous Administration of Furosemide. Medical Devices Evidence and Research. Volume 17. 229–235. 1 indexed citations
2.
Konstam, Marvin A., Joseph M. Massaro, Ravi Dhingra, et al.. (2024). Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure. JACC Heart Failure. 12(11). 1830–1841. 6 indexed citations
3.
Zilberberg, Marya D., Brian H. Nathanson, Kate Sulham, et al.. (2023). Examining the Burden of Potentially Avoidable Heart Failure Hospitalizations. ClinicoEconomics and Outcomes Research. Volume 15. 721–731. 2 indexed citations
4.
Zilberberg, Marya D., et al.. (2023). Descriptive Epidemiology and Outcomes of Patients with Short Stay Hospitalizations for the Treatment of Congestive Heart Failure in the US. ClinicoEconomics and Outcomes Research. Volume 15. 139–149. 4 indexed citations
5.
Mohr, John, et al.. (2022). From Oral to Subcutaneous Furosemide: The Road to Novel Opportunities to Manage Congestion. Structural Heart. 6(4). 100076–100076. 8 indexed citations
6.
Ferry, Tristan, Thomas P. Lodise, Jason C Gallagher, et al.. (2020). Outpatient Subcutaneous Antimicrobial Therapy (OSCAT) as a Measure to Improve the Quality and Efficiency of Healthcare Delivery for Patients With Serious Bacterial Infections. Frontiers in Medicine. 7. 585658–585658. 10 indexed citations
7.
Fitch, Kathryn, et al.. (2018). The cost impact to Medicare of shifting treatment of worsening heart failure from inpatient to outpatient management settings. ClinicoEconomics and Outcomes Research. Volume 10. 855–863. 14 indexed citations
8.
9.
Olesky, Melanie, et al.. (2016). National Prevalence of Carbapenem-Resistant Enterobacteriaceae in the Ambulatory and Acute Care Settings in the United States in 2015. Open Forum Infectious Diseases. 3(suppl_1). 3 indexed citations
10.
Frei, Christopher R., Jamie C. Barner, Christine U. Oramasionwu, et al.. (2010). Influenza vaccination rates among pharmacists. Journal of the American Pharmacists Association. 50(4). 517–522. 10 indexed citations
11.
Kuper, Kristi, et al.. (2009). Antimicrobial Susceptibility Testing: A Primer for Clinicians. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 29(11). 1326–1343. 60 indexed citations
12.
Mohr, John, Lawrence V. Friedrich, Sara Yankelev, & Kenneth C. Lamp. (2009). Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin® Outcomes Registry and Experience (CORE). International Journal of Antimicrobial Agents. 33(6). 543–548. 56 indexed citations
13.
Mohr, John, et al.. (2008). Current Options in Antifungal Pharmacotherapy. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 28(5). 614–645. 59 indexed citations
14.
Mohr, John, et al.. (2008). Risk factors for hyperglycemia in hospitalized adults receiving gatifloxacin: A retrospective, nested case-controlled analysis. Clinical Therapeutics. 30(1). 152–157. 7 indexed citations
15.
Mohr, John, et al.. (2008). Dysglycaemias and Fluoroquinolones. Drug Safety. 31(4). 283–292. 23 indexed citations
16.
Mohr, John. (2008). Update on the Efficacy and Tolerability of Meropenem in the Treatment of Serious Bacterial Infections. Clinical Infectious Diseases. 47(s1). S41–S51. 54 indexed citations
17.
Lodise, Thomas P., Jeffrey Graves, Chris D. Miller, et al.. (2007). Effects of Gatifloxacin and Levofloxacin on Rates of Hypoglycemia and Hyperglycemia Among Elderly Hospitalized Patients. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 27(11). 1498–1505. 16 indexed citations
18.
Mohr, John, Andrea C. Hall, Charles D. Ericsson, & Luis Ostrosky‐Zeichner. (2005). Fatal Amphotericin B Overdose Due to Administration of Nonlipid Formulation Instead of Lipid Formulation. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 25(3). 426–428. 11 indexed citations
19.
Mohr, John, et al.. (2005). A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 25(10). 1303–1309. 68 indexed citations
20.
Mohr, John, Audrey Wanger, & John Rex. (2004). Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagnostic Microbiology and Infectious Disease. 48(2). 125–130. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katie E. Barber Breakdown of academic impact, for papers by Brian J. Werth Breakdown of academic impact, for papers by H. David Friedland Breakdown of academic impact, for papers by Jon Bruss Breakdown of academic impact, for papers by Christopher W. Crank Breakdown of academic impact, for papers by Chris M. Pillar Breakdown of academic impact, for papers by Pamela Moise Breakdown of academic impact, for papers by Deborah C. Draghi Breakdown of academic impact, for papers by Sorana Segal‐Maurer Breakdown of academic impact, for papers by James C. Hurley
Rankless by CCL
2026